SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engage